Delcath Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023 at 05:25 pm EDT
Share
Delcath Systems, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.495 million compared to USD 0.797 million a year ago. Net loss was USD 7.2 million compared to USD 10.16 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 1.24 a year ago. Diluted loss per share from continuing operations was USD 0.58 compared to USD 1.24 a year ago.
For the six months, revenue was USD 1.09 million compared to USD 1.17 million a year ago. Net loss was USD 16.2 million compared to USD 19.16 million a year ago. Basic loss per share from continuing operations was USD 1.35 compared to USD 2.34 a year ago. Diluted loss per share from continuing operations was USD 1.35 compared to USD 2.34 a year ago.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).